Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
复制标题
DOI：
10.1016/j.hoc.2017.01.009
复制
发表时间：
2017-06
期刊：
影响因子：
--
通讯作者：
Catenacci DVT
中科院分区：
文献类型：
--
作者：
Maron SB;Catenacci DVT
胃食管癌（GEC）仍然是全球癌症相关死亡的主要原因。尽管美国远端胃腺癌（GC）的发病率正在下降，但近端食管胃交界处腺癌（EGJ）的发病率正在上升。GC和EGJ一起在转移性环境中作为GEC统一治疗。转移性环境中的总生存期仍然很差，迄今为止，很少有分子靶向方法成功纳入常规护理-仅用于ERBB 2扩增的一线抗HER 2治疗和二线抗VEGFR 2治疗。在这里，我们审查表皮生长因子受体，MET和ERBB 2，其治疗意义，以及未来的方向，在针对这些途径的畸变。
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) incidence is rising. GC and EGJ, together, are treated uniformly in the metastatic setting as GEC. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to date – only first line anti-HER2 therapy for ERBB2 amplification and second line anti-VEGFR2 therapy. Here we review aberrations in EGFR, MET, and ERBB2, their therapeutic implications, and future directions in targeting these pathways.